Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.76 |
| ▸ | LMNA | P02545 | 3/20 | 0.76 |
| ▸ | MAPT | P10636 | 3/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.76 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.76 |
| ▸ | RECQL | P46063 | 1/20 | 0.76 |
| ▸ | STS | P08842 | 8/20 | 0.74 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.74 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | ESR1 | P03372 | 3/20 | 0.70 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.70 |
| ▸ | CA1 | P00915 | 2/20 | 0.70 |
| ▸ | CA2 | P00918 | 2/20 | 0.70 |
| ▸ | CA9 | Q16790 | 2/20 | 0.70 |
| ▸ | CA4 | P22748 | 1/20 | 0.70 |
| ▸ | CA6 | P23280 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estrone Acetate SCHEMBL6241050 | 1.00 | CYP3A4 (0.76) | CYP3A4LMNAMAPTSMN1; SMN2HSD17B1 | |
| Estrone Acetate SCHEMBL20006536 | 1.00 | CYP3A4 (0.76) | CYP3A4LMNAMAPTSMN1; SMN2HSD17B1 | |
| SCHEMBL1977541 | 0.94 | CYP3A4 (0.80) | CYP3A4LMNAMAPTSMN1; SMN2HSD17B1 | |
| SCHEMBL12216745 | 0.90 | CYP3A4 (0.75) | CYP3A4LMNAMAPTSMN1; SMN2HSD17B1 | |
| SCHEMBL9790047 | 0.89 | CYP3A4 (0.74) | CYP3A4LMNAMAPTSMN1; SMN2HSD17B1 | |
| SCHEMBL7989780 | 0.89 | CYP3A4 (0.74) | CYP3A4LMNAMAPTSMN1; SMN2HSD17B1 | |
| SCHEMBL6899365 | 0.89 | ESR1 (0.69) | CYP3A4LMNAMAPTSMN1; SMN2HSD17B1 | |
| SCHEMBL6899367 | 0.89 | ESR1 (0.69) | CYP3A4LMNAMAPTSMN1; SMN2HSD17B1 | |
| SCHEMBL7992527 | 0.89 | CYP3A4 (0.72) | CYP3A4LMNAMAPTSMN1; SMN2HSD17B1 | |
| SCHEMBL27592877 | 0.89 | CYP3A4 (0.72) | CYP3A4LMNAMAPTSMN1; SMN2HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 583 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| EP-2744771-B1 | C-HALOGEN BOND FORMATION | UNIV PRINCETON (US) | 2020-10-21 | — | — | EP | claimed |
| US-20200190012-A1 | C-HALOGEN BOND FORMATION | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2020-06-18 | — | — | US | claimed |
| EP-3651746-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | Hera Health Solutions Inc. (US) | 2020-05-20 | — | — | EP | claimed |
| CN-111032024-A | Bioerodible drug delivery implant | 赫拉健康解决方案公司 | 2020-04-17 | — | — | CN | claimed |
| US-20190127311-A1 | C-HALOGEN BOND FORMATION | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2019-05-02 | — | — | US | claimed |
| US-10196341-B2 | C-halogen bond formation | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2019-02-05 | — | — | US | claimed |
| WO-2019014076-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | HERA HEALTH SOLUTIONS INC. (US) | 2019-01-17 | — | — | WO | claimed |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | claimed |
| US-20140249329-A1 | C-HALOGEN BOND FORMATION | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2014-09-04 | — | — | US | claimed |
| WO-2000042955-A1 | DRUG DOSAGE UNIT FOR BUCCAL ADMINISTRATION OF STEROIDAL ACTIVE AGENTS | PLACE VIRGIL A (US) | 2000-07-27 | — | — | WO | claimed |
| EP-0500793-B1 | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL | ALZA CORP (US) | 1993-11-03 | — | — | EP | claimed |
| EP-0472645-B1 | OSMOTIC DOSAGE FORM | ALZA CORPORATION (US) | 1993-07-14 | — | — | EP | claimed |
| US-5200197-A | Contraceptive pill | ALZA CORPORATION (US) | 1993-04-06 | — | — | US | claimed |
| EP-0500793-A1 | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL. | ALZA CORP (US) | 1992-09-02 | — | — | EP | claimed |
| US-5098714-A | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL | ALZA CORPORATION (US) | 1992-03-24 | — | — | US | claimed |
| EP-0472645-A1 | OSMOTIC DOSAGE FORM. | ALZA CORP (US) | 1992-03-04 | — | — | EP | claimed |
| WO-1991007173-A1 | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL | ALZA CORPORATION (US) | 1991-05-30 | — | — | WO | claimed |
| WO-1990014075-A1 | OSMOTIC DOSAGE FORM | ALZA CORPORATION (US) | 1990-11-29 | — | — | WO | claimed |
| US-4948593-A | SUSTAINED AND CONTROLLED CONTRACEPTION | ALZA CORPORATION (US) | 1990-08-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190012-A1 | C-HALOGEN BOND FORMATION | CBR3, FOS, CBR1 | CYP3A4 1365/4885LMNA 1963/4885MAPT 4035/4885 |
| US-20190127311-A1 | C-HALOGEN BOND FORMATION | CBR3, FOS, CBR1 | CYP3A4 1365/4885LMNA 1963/4885MAPT 4035/4885 |
| US-20140249329-A1 | C-HALOGEN BOND FORMATION | CBR3, FOS, CBR1 | CYP3A4 1365/4885LMNA 1963/4885MAPT 4035/4885 |
| US-10196341-B2 | C-halogen bond formation | CBR3, FOS, CBR1 | CYP3A4 1365/4885LMNA 1963/4885MAPT 4035/4885 |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | CYP3A4 867/4885LMNA 1578/4885MAPT 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.